Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 9/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | GLP1R | P43220 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19781595 | 1.00 | FGFR1 (0.56) | FGFR1KCNH2HTTALDH1A1MAPT | |
| SCHEMBL19781537 | 0.83 | KCNH2 (0.55) | FGFR1KCNH2HTTALDH1A1MAPT | |
| SCHEMBL19781251 | 0.83 | FGFR1 (0.58) | FGFR1KCNH2HTTALDH1A1MAPT | |
| SCHEMBL19781253 | 0.82 | FGFR1 (0.60) | FGFR1KCNH2HTTALDH1A1MAPT | |
| SCHEMBL15213070 | 0.81 | FGFR1 (0.67) | FGFR1HTTALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21436064 | 0.81 | GABRP (0.43) | FGFR1KCNH2HTTALDH1A1MAPT | |
| SCHEMBL19781769 | 0.79 | FGFR1 (0.56) | FGFR1HTTALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL19781511 | 0.78 | FGFR1 (0.59) | FGFR1HTTALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL19781506 | 0.75 | FGFR1 (0.49) | FGFR1KCNH2ALDH1A1MAPTHPGD | |
| SCHEMBL19781604 | 0.75 | KCNH2 (0.48) | FGFR1KCNH2HTTALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281825-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281825-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | C9, C1S, ZC3HAV1 | FGFR1 3952/4885KCNH2 88/4885HTT 1349/4885 |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | C9, C1R, C1S | FGFR1 3928/4885KCNH2 107/4885HTT 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.